Pfizer Corporation

Icagen, Inc.

Thomas Ryckmans

Justin Stephen Bryans

Patrick Stephen Johnson

Alan Stobie

Paul Anthony Stupple

David James Rawson

Karl Richard Gibson

Andrew Douglas Baxter

Alan Daniel Brown

Mark Edward Bunnage

Mark David Andrews

Sharanjeet Kaur Bagal

Sarah Elizabeth Skerratt

Kiyoyuki Omoto

Brian Edward Marron

Gavin Alistair Whitlock

Kevin Neil Dack

Nigel Alan Swain

Lee Richard Roberts

Robert Ian Storer

Russell Andrew Lewthwaite

Paul Vincent Fish

Florian Michel Wakenhut

David Graham Brown

Christopher William West

Yogesh Sabnis

Marcel John De Groot

Julie Newman

Wolfgang Klute

Inaki Morao

Robert Duncan Armour

Toby James Underwood

Helen Janet Mason

The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.

Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors

Pyrrolo[2,3-d]pyrimidine tropomysin-related kinase inhibitors

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new sulfonamide Nav1.7 inhibitors of formula (I): or pharmaceutically acceptable salts thereof, wherein Z, R, R, R, R, R, Rand Rare as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

Chemical compounds

The present invention provides compounds of formula (I), or pharmaceutically acceptable derivatives thereof wherein the variables Z, Q, Ring A, V, X, Y and Y' are as defined herein, and pharmaceutical compositions comprising these compounds. The compounds of formula (I) and pharmaceutical compositions comprising them are useful for treating a disorder for which a V1a antagonist is indicated, in particular, dysmenorrhoea.

Compounds useful in therapy

Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein:

Triazole derivatives which inhibit vasopressin antagonistic activity

A compound of formula (I), or a pharmaceutically acceptable derivative, wherein A, B, V, W, X, Y, and Z are as defined herein; pharmaceutical compositions thereof; and uses thereof.

Triazole compounds useful in therapy

A compound of Formula (I) and pharmaceutically and/or veterinarily acceptable derivatives thereof, wherein:

Amides useful as monoamine re-uptake inhibitors

A compound of formula (I), or a pharmaceutically acceptable derivative thereof, wherein A, B, V, W, X, Y, and Z are as defined herein; pharmaceutical compositions thereof; and uses thereof.

The invention provides compounds of formula (I), the pharmaceutically acceptable salts and solvates thereof, wherein A, B, R, R, and Rare as defined herein; pharmaceutical compositions thereof; combinations thereof; and uses thereof as vasopressin Vantagonists.

Growing community of inventors

Sandwich, United Kingdom

Thomas Ryckmans